RxDoctor Payments Data

Muhammad Shabbir, MD

Family Medicine · Warren, MINPI 1447560818

Payments from drug & device makers

$572in general payments, 2019–2025

Across 25 payments — averaging $22.87 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AstraZeneca$146
  • Novartis$98
  • AbbVie$63
  • Novo Nordisk$40
  • Pfizer$35
  • Lilly USA, LLC$29
  • plus $161 from 8 others

What the payments were for

  • Food & beverage$572100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
21
22
23
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$572 in reported general payments places this provider in the 60th percentile of 3,945 family medicine providers in Michigan.

See all family medicine providers in Michigan

Medicare billing

Part B allowed, 2024
$112,131
Medicare patients
416
Services billed
1,980

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
OzempicSemaglutide27$35,921
JardianceEmpagliflozin21$28,005
XareltoRivaroxaban19$26,697
EliquisApixaban18$25,341
TrulicityDulaglutide14$25,005
JanuviaSitagliptin Phosphate14$19,178
Atorvastatin Calcium312$3,213
Levothyroxine Sodium228$2,816
Rosuvastatin Calcium203$2,745
Omeprazole134$2,316
Ezetimibe53$1,759
Amlodipine Besylate214$1,712
SynthroidLevothyroxine Sodium19$1,453
Albuterol Sulfate HfaAlbuterol Sulfate46$1,294
Metoprolol Succinate96$1,289

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Novo NordiskOzempic$40$35,92127 claims
Boehringer IngelheimJardiance$19$28,00521 claims
PfizerEliquis$35$25,34118 claims
Lilly USA, LLCTrulicity$29$25,00514 claims
AbbVieSynthroid$63$1,45319 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 60th percentile of 3,945 family medicine providers in Michigan.

Other family medicine in Warren

See the full list for Michigan

Where these figures come from

Is this you, or does something look wrong? →